228 related articles for article (PubMed ID: 16765186)
1. Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy.
Clark PE; Hall MC; Borden LS; Miller AA; Hu JJ; Lee WR; Stindt D; D'Agostino R; Lovato J; Harmon M; Torti FM
Urology; 2006 Jun; 67(6):1257-61. PubMed ID: 16765186
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy.
Lin AM; Rini BI; Weinberg V; Fong K; Ryan CJ; Rosenberg JE; Fong L; Small EJ
BJU Int; 2006 Oct; 98(4):763-9. PubMed ID: 16796694
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial of lycopene supplementation in Tobago men with high prostate cancer risk.
Bunker CH; McDonald AC; Evans RW; de la Rosa N; Boumosleh JM; Patrick AL
Nutr Cancer; 2007; 57(2):130-7. PubMed ID: 17571945
[TBL] [Abstract][Full Text] [Related]
4. Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease.
Zietman AL; Dallow KC; McManus PA; Heney NM; Shipley WU
Urology; 1996 Feb; 47(2):236-9. PubMed ID: 8607241
[TBL] [Abstract][Full Text] [Related]
5. A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer.
Ryan CJ; Harzstark AH; Rosenberg J; Lin A; Claros C; Goldfine ID; Kerner JF; Small EJ; Youngren JF
BJU Int; 2008 Feb; 101(4):436-9. PubMed ID: 18234062
[TBL] [Abstract][Full Text] [Related]
6. Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trial.
Rosenbaum E; Zahurak M; Sinibaldi V; Carducci MA; Pili R; Laufer M; DeWeese TL; Eisenberger MA
Clin Cancer Res; 2005 Jun; 11(12):4437-43. PubMed ID: 15958628
[TBL] [Abstract][Full Text] [Related]
7. Lycopene for advanced hormone refractory prostate cancer: a prospective, open phase II pilot study.
Schwenke C; Ubrig B; Thürmann P; Eggersmann C; Roth S
J Urol; 2009 Mar; 181(3):1098-103. PubMed ID: 19150092
[TBL] [Abstract][Full Text] [Related]
8. Lycopene and soy isoflavones in the treatment of prostate cancer.
Vaishampayan U; Hussain M; Banerjee M; Seren S; Sarkar FH; Fontana J; Forman JD; Cher ML; Powell I; Pontes JE; Kucuk O
Nutr Cancer; 2007; 59(1):1-7. PubMed ID: 17927495
[TBL] [Abstract][Full Text] [Related]
9. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
Bruchovsky N; Klotz L; Crook J; Goldenberg SL
Cancer; 2007 Mar; 109(5):858-67. PubMed ID: 17265527
[TBL] [Abstract][Full Text] [Related]
10. Lycopene: a novel drug therapy in hormone refractory metastatic prostate cancer.
Ansari MS; Gupta NP
Urol Oncol; 2004; 22(5):415-20. PubMed ID: 15464923
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy.
Bajaj GK; Zhang Z; Garrett-Mayer E; Drew R; Sinibaldi V; Pili R; Denmeade SR; Carducci MA; Eisenberger MA; DeWeese TL
Urology; 2007 Mar; 69(3):526-31. PubMed ID: 17382158
[TBL] [Abstract][Full Text] [Related]
12. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
Montgomery RB; Nelson PS; Lin D; Ryan CW; Garzotto M; Beer TM
Cancer; 2007 Sep; 110(5):996-1002. PubMed ID: 17639587
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer.
Siemens DR; Heaton JP; Adams MA; Kawakami J; Graham CH
Urology; 2009 Oct; 74(4):878-83. PubMed ID: 19476985
[TBL] [Abstract][Full Text] [Related]
14. Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up.
Bañez LL; Blake GW; McLeod DG; Crawford ED; Moul JW
BJU Int; 2009 Aug; 104(3):310-4. PubMed ID: 19239458
[TBL] [Abstract][Full Text] [Related]
15. Phase II study evaluating oral triamcinolone in patients with androgen-independent prostate cancer.
Srinivas S; Krishnan AV; Colocci N; Feldman D
Urology; 2006 May; 67(5):1001-6. PubMed ID: 16698360
[TBL] [Abstract][Full Text] [Related]
16. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial.
King CR; Brooks JD; Gill H; Pawlicki T; Cotrutz C; Presti JC
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1043-8. PubMed ID: 18755555
[TBL] [Abstract][Full Text] [Related]
18. Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy.
Kucuk O; Sarkar FH; Sakr W; Djuric Z; Pollak MN; Khachik F; Li YW; Banerjee M; Grignon D; Bertram JS; Crissman JD; Pontes EJ; Wood DP
Cancer Epidemiol Biomarkers Prev; 2001 Aug; 10(8):861-8. PubMed ID: 11489752
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer.
Liu G; Oettel K; Ripple G; Staab MJ; Horvath D; Alberti D; Arzoomanian R; Marnocha R; Bruskewitz R; Mazess R; Bishop C; Bhattacharya A; Bailey H; Wilding G
Clin Cancer Res; 2002 Sep; 8(9):2820-7. PubMed ID: 12231522
[TBL] [Abstract][Full Text] [Related]
20. Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor.
Rini BI; Fong L; Weinberg V; Kavanaugh B; Small EJ
J Urol; 2006 Jun; 175(6):2087-91. PubMed ID: 16697809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
